Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Boehringer Ingelheim presents pramipexole results

Boehringer Ingelheim presents pramipexole results

26th August 2008

Boehringer Ingelheim has announced the publication of data highlighting key continuing studies of pramipexole in a number of Parkinson’s disease research areas.

At the congress of the European Federation of Neurological Sciences (EFNS) held in Madrid, discussions covered clinical benefits of early treatment initiation, management of depressive symptoms related to Parkinson’s Disease and a new formulation of pramipexole currently being investigated.

Known under a variety of trade names, including Mirapexin, Sifrol, Mirapex and Pexola, parmipexole is a compound approved in 1997 as a monotherapy or combination treatment with levodopa for the signs and symptoms of idiopathic Parkinson’s disease.

The compound is currently marketed in more than 70 countries across the world and was approved in 2006 for the symptomatic treatment of moderate-to-severe idiopathic restless legs syndrome (RLS).

Professor Anthony Schapira, chairman of the University Department of Clinical Neurosciences at the Institute of Neurology, Queen Square, UCL, said: “The debate on when and how to treat early Parkinson’s disease patients has been ongoing.

“Currently, treatment would typically be initiated when symptoms have caused disability.”

He added it is a major therapeutic priority to provide medical evidence for a treatment to prevent the progression of the disease, with the Proud study results presented at the EFNS conference looking to shed more light on this question.

In June 2008, Boehringer Ingelheim announced the publication of new data showing that pramipexole can significantly reduce limb pain in patients with RLS.

We currently have 5 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.